Global biopharmaceutical company Pfizer announced the launch of a $1 billion sustainability bond offering, with the use of proceeds including funding R&D and capex for the company’s COVID-19 vaccine.
The 10-year bond has been priced at 1.75%, and Pfizer anticipates the closing of the offering to occur this week. The issue marks the second for Pfizer under its Sustainability Bond Framework, following a $1.25 billion 2.625% 10-year offering in March of last year.
According to the company, proceeds from the offering will be used to finance or refinance research and development expenses related to COVID-19 vaccine research and development, capital expenditures in connection with the manufacture and distribution of COVID-19 vaccines, and other projects of Pfizer or any of its subsidiaries that have Environmental criteria consider how a company performs as a steward of nature. More and/or Social criteria examine how it manages relationships with employees, suppliers, customers, and the communities where it operates. More benefits.
The post Pfizer Issues $1 Billion Sustainability Bond, Proceeds to Fund COVID-19 Vaccine R&D appeared first on ESG Today.